从月经到更年期的抗凝药管理:临床管理工具包
Divyaswathi Citla-Sridhar1, Shruti Karanth2, Andrea Van Beek3
1Department of Pediatrics, University of Arkansas for Medical Sciences/Arkansas Children's hospital, Little Rock, Arkansas, USA. Electronic address: https://x.com/DivyaCitlaMD.
Journal of thrombosis and haemostasis : JTH
|December 10, 2025
概括
对于月经期的个体来说,管理抗凝血药需要专门的护理. 该工具包提供有关月经出血,避孕和生殖健康的指导,以改善患者的治疗结果.
科学领域:
- 血液学 血液学 血液学
- 妇科 妇科 妇科 妇科
- 生殖健康 生殖健康
背景情况:
- 目前的临床指南缺乏针对月经期患者服用抗凝药的具体建议.
- 现有的指导方针对这一群体的月经出血,避孕和生殖过渡提供了有限的建议.
研究的目的:
- 开发一种实用的临床工具包,用于在月经的人群中进行抗凝血管理.
- 解决与月经出血,避孕和生殖健康有关的护理缺口.
主要方法:
- 创建了一个由专家驱动的资源,概述了最佳实践.
- 该工具包涵盖了大量月经出血的识别和管理,避孕咨询和高风险时期的护理协调.
- 为特殊人群提供指导,包括青少年,变性人和性别多元的人,以及那些获得护理机会有限的人.
主要成果:
- 该工具包提供了关于药物选择,剂量调整,贫血查和妇科转诊的指导.
- 它强调了多学科团队 (血液学,妇科,初级保健,抗凝血服务) 的重要性.
- 突出了将月经健康纳入抗凝管理和促进共享决策的战略.
结论:
- 这套工具旨在改善以患者为中心的,公平的护理,为月经期间服用抗凝药的人提供治疗.
- 它有助于将月经健康整合到常规抗凝管理中.
- 该资源促进了共享决策,并提高了受影响个人的生活质量.
相关概念视频
Venous Thrombosis III: Interprofessional Care
262
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
262
Venous Thrombosis IV: Nursing Management
182
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
182
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.0K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.0K
Anticoagulant Drugs: Low-Molecular-Weight Heparins
1.6K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.6K
Hormonal Regulation of the Menstrual Cycle
1.4K
The ovarian cycle regulates endometrial changes throughout a single menstrual cycle via the coordinated action of gonadotrophin-releasing hormone (GnRH) and gonadotrophins.
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH...
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH...
1.4K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
1.0K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.0K


